- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05796193
Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire
The investigator plan to conduct a three-arm cluster-randomized control trial which compares two next generation of long-lasting Insecticidal Nets (LLINs); Veeralin®LLIN (PBO-py LLIN), Interceptor G2 (chlorfenapyr-py LLIN) to a standard py-LLIN in the department of Tiebissou Southern Bouake city, central Côte d'Ivoire.
The primary objective of the project is to evaluate the efficacy of chlorfenapyr-pyrethroid and piperonyl-butoxide (PBO) synergist-pyrethroid LLINs on malaria case incidence in children aged 6 months to 10 years compared to standard pyrethroid-only LLINs. The secondary objectives are to evaluate the efficacy of the two intervention LLINs compared to the standard LLIN on a) malaria infection prevalence in the general population (both children and adults), b) vector density and c) entomological inoculation rate (EIR) (as a proxy for malaria transmission). In addition, changes in phenotypic resistance intensity and selection for molecular resistance mechanisms at baseline and 12 months post-LLIN distribution, in sentinel villages in each treatment arm will be investigate.
It is vital to demonstrate that these next generation LLINs which are becoming the standard of care in Sub Saharan AFRICA, are superior to standard py-LLIN in the most extreme resistance areas as this is likely where alternative interventions will be most needed to keep malaria control on track. The trial will generate the first epidemiological evidence on the efficacy of PBO nets compared to py-LLIN in West Africa.
Study Overview
Status
Conditions
Detailed Description
Background: The massive scale-up of long-lasting insecticidal nets (LLIN) has led to a major reduction in malaria burden in many sub-Saharan African (SSA) countries. This progress is threatened by the wide scale selection of insecticide resistant malaria vectors.
Study site: The study will be conducted in the department of Tiebissou (Gbeke Region in Lac district) Southern Bouake city, central Côte d'Ivoire. The Lac district is characterized by intense indoor malaria transmission with a prevalence of malaria reaching 51.3% in 2021 in children of under 5 years of age and extremely high pyrethroid resistance intensity in the main malaria vectors Anopheles gambiae s.s. and An. coluzzii.
Study design: Three-arm superiority, single blinded, cluster-randomised trial with village as the unit of randomisation. The arms consist of; 1/ Veeralin LLIN, a net combining the synergist PBO and the pyrethroid alpha-cypermethrin, 2/Interceptor G2, a mixture LLIN incorporating two adulticides with different modes of action; chlorfenapyr and a pyrethroid (alpha-cypermethrin), and 3/ the control arm: MAGNet LLIN, an alpha-cypermethrin-only LLIN.
Activities/Sample size:
A total of 33 villages (1 village = 1 cluster) with an average of 200 households will be identified and mapped. Nets will be distributed at a central point following national guidelines with 1 net for every 2 people.
To compare incidence of malaria cases between each intervention study arm and the control arm, a cohort of 50 children (45 + 5 to account for loss to follow up) will be recruited per cluster in 33 clusters for 12 months follow up to be able to detect a 35% relative reduction in malaria cases per child per year (rate ratio 0.65) between the intervention and the reference arms, assuming transmission in the control arm is 1.2 malaria cases per year with a coefficient of variation of 0.29 between clusters. The children will be visited twice a month during the transmission season (April to November) and once a month during the dry season.
Malaria infection prevalence cross-sectional surveys will be conducted, at baseline, 6 and 12 months after LLIN distribution. 50 people of all ages will be randomly selected from each of the 33 clusters (11 clusters per arm x 3 arms) and tested for malaria using RDT. The study will have 80% power to detect a relative 35% lower prevalence (prevalence ratio 0.65 in each intervention arm (VEERALLIN or Interceptor G2) relative to standard LLIN, assuming a prevalence of 50% in the control arm and a coefficient of variation of 0.3.
Vector density over 12 months will be followed using Human Landing Collection (HLC) indoor and outdoor with collection in 6 households in every cluster every 2 months. Assuming a mean mosquito density of 28 in the control arm, and a 60% reduction in mosquitoes in the intervention arms, with a coefficient of variation of 0.55 between clusters, this will give 80% power to detect differences at each timepoint.
Insecticide resistance intensity will be monitored at baseline and post intervention using adapted CDC bottle assays. The mechanism involved in resistance to pyrethroid and chlorfenapyr will be screened.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Raphael NGUESSAN, PhD
- Phone Number: +225 0779404001
- Email: raphael.n'guessan@lshtm.ac.uk
Study Contact Backup
- Name: Aphonsine KOFFI, PhD
- Phone Number: +225 0707620886
- Email: koffi_alphonsine@yahoo.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- For adults: willing to participate and provide consent
- For children: Having a parents/adult caregiver willing to provide written consent for the household and clinical survey and assent for children over 10
- Residing in the village over the last 3 months
- Be aged 6 months to 9 years old at time of recruitment (for the cohort)
Exclusion Criteria:
- Children who are expected to be non-resident over the period of study will be excluded (for the cohort)
- Dwelling not found or vacant during the survey (for prevalence and entomological surveys)
- No adult caregiver capable to give informed consent (All activities)
- Habitants/selected participants severely ill
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Py-PBO LLIN
Veeralin is a long-lasting net of 130 deniers containing the pyrethroid insecticide alpha-cypermethrin 6.0 g/kg (216 mg/m2) and the synergist piperonyl butoxide (PBO) 2.2 g/kg (79.2 mg/m2) and manufactured by VKA polymers.
|
Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
|
Experimental: Py-CFP LLIN
Interceptor® G2 is a long-lasting dual insecticide treated nets of 100 deniers combining Alpha-cypermethrin 2.4 g/kg (100 mg/m2) and Chlorfenapyr 4.8 g/kg (200 mg/m2) manufactured by BASF
|
Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
|
Active Comparator: Py LLIN
MAGNet® is a long-lasting net of 150 deniers containing the pyrethroid insecticide alpha-cypermethrin 5.8 g/kg (261 mg/m2) only and manufactured by VKA polymers.
|
reference: standard pyrethroid LLIN
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
malaria case incidence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]
Time Frame: Over one year follow up
|
Incidence of malaria cases (fever above 37.5C or history of a fever in the last 48 hours and a positive RDT) in children aged 6 months to 10 years.
|
Over one year follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Malaria infection prevalence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]
Time Frame: Baseline
|
Malaria infection prevalence (by RDT) in the study population of all ages
|
Baseline
|
Malaria infection prevalence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]
Time Frame: 6 months post intervention
|
Malaria infection prevalence (by RDT) in the study population of all ages
|
6 months post intervention
|
Malaria infection prevalence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]
Time Frame: 12 months post intervention
|
Malaria infection prevalence (by RDT) in the study population of all ages
|
12 months post intervention
|
Vector Density per person per night using human indoor and outdoor landing catches
Time Frame: Over one year follow up
|
Indoor and outdoor Anopheles density per night per person
|
Over one year follow up
|
Sporozoite rate in Anopheles detected using Enzyme Linked Immuno-Sorbent Assay (ELISA) circumsporozoite protein technique. landing catches
Time Frame: Over one year follow up
|
Proportion of Anopheles with malaria circumsporozoites in salivary gland
|
Over one year follow up
|
Mean number of Plasmodium spp infective malaria vectors collected per person per night
Time Frame: Over one year follow up
|
Entomological inoculation rate measure as vector density x sporozoite rate
|
Over one year follow up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
gSG6-P1 IgG seroprevalence using ELISA technique
Time Frame: baseline
|
Serological responses to mosquito salivary peptides: Blood spots on filter paper will be utilized to measure the level of antibodies in residents blood as a proxy for exposure to mosquito bites
|
baseline
|
gSG6-P1 IgG seroprevalence using ELISA technique
Time Frame: 12 months post intervention
|
Serological responses to mosquito salivary peptides: Blood spots on filter paper will be utilized to measure the level of antibodies in residents blood as a proxy for exposure to mosquito bites
|
12 months post intervention
|
30 minutes mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay
Time Frame: Baseline
|
Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted
|
Baseline
|
24 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay
Time Frame: Baseline
|
Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted
|
Baseline
|
72 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay
Time Frame: Baseline
|
Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted
|
Baseline
|
30 minutes mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay
Time Frame: 12 months post intervention
|
Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted
|
12 months post intervention
|
24 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay
Time Frame: 12 months post intervention
|
Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted
|
12 months post intervention
|
72 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay
Time Frame: 12 months post intervention
|
Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted
|
12 months post intervention
|
Relative fold change in expression of metabolic genes
Time Frame: Baseline
|
Selection for resistance will be monitored by measuring changes in levels of metabolic enzyme expression between wild population of Anopheles and susceptible reference Anopheles
|
Baseline
|
Relative fold change in expression of metabolic genes
Time Frame: 12 months post intervention
|
Selection for resistance will be monitored by measuring changes in levels of metabolic enzyme expression between wild population of Anopheles and susceptible reference Anopheles
|
12 months post intervention
|
Concentration of PBO, alpha-cypermethrin and Chlorfenapyr in g per kg in mosquito net
Time Frame: Before net distribution
|
Concentration of chemical will be assessed by HPLC
|
Before net distribution
|
24 hours and 72 hours mortality in a susceptible colony of Anopheles gambiae after exposure to new pieces of mosquito nets
Time Frame: Before net distribution
|
Bio-efficacy testing will be conducted in standard WHO cone bio-assay and/or tunnel test
|
Before net distribution
|
24 hours and 72 hours mortality in a resistant colony of Anopheles gambiae after exposure to new pieces of mosquito nets
Time Frame: Before net distribution
|
Bio-efficacy testing will be conducted in standard WHO cone bio-assay and/or tunnel test
|
Before net distribution
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 28390
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
Clinical Trials on Alpha-cypermethrin and PBO LLIN
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of California, IrvineActive, not recruitingLLIN, PBO LLIN, IRS, LarvicidingUnited States, Kenya
-
London School of Hygiene and Tropical MedicineUniversity of Ottawa; National Institute for Medical Research, Tanzania; Kilimanjaro...Completed
-
Alkermes, Inc.Completed
-
Merck Sharp & Dohme LLCCompletedStaphylococcus Aureus Infection
-
PATHTulane University; Liverpool School of Tropical Medicine; Ministry of Health,... and other collaboratorsCompleted
-
London School of Hygiene and Tropical MedicineCompletedMalaria | AnaemiaTanzania
-
Palatin Technologies, IncCompletedHypoactive Sexual Desire DisorderUnited States, Canada
-
Eisai Inc.Purdue Pharma LPCompleted
-
Palatin Technologies, IncAMAG Pharmaceuticals, Inc.CompletedHypoactive Sexual Desire DisorderUnited States, Canada